To block infection from HIV, a successful vaccine will require a combination of ingredients, including at least three antibody targets and a substance that boosts immune responses.
To block infection from HIV, a successful vaccine will require a combination of ingredients, including at least three antibody targets and a substance that boos
The National Institute of Allergy and Infectious Diseases has awarded $17.5 million over three years to the Duke Human Vaccine Institute to develop a vaccine that protects against multiple types of coronaviruses and viral variants.
DURHAM - The National Institute of Allergy and Infectious Diseases (NIAID) has awarded $17.5 million over three years to the Duke Human Vaccine Institute to
E-Mail
DURHAM, N.C. - A newly identified group of antibodies that binds to a coating of sugars on the outer shell of HIV is effective in neutralizing the virus and points to a novel vaccine approach that could also potentially be used against SARS-CoV-2 and fungal pathogens, researchers at the Duke Human Vaccine Institute report.
In a study appearing online May 20 in the journal
Cell, the researchers describe an immune cell found in both monkeys and humans that produces a unique type of anti-glycan antibody. This newly described antibody has the ability to attach to the outer layer of HIV at a patch of glycans the chain-like structures of sugars that are on the surfaces of cells, including the outer shells of viruses.